Home > News > Management of Cardiovascular Risk Factors in Racial and Ethnic Minorities with Type-2 Diabetes
Cardiovascular Risk, Diabetes
Read Time: 3 mins

Management of Cardiovascular Risk Factors in Racial and Ethnic Minorities with Type-2 Diabetes

Published Online: June 6th 2011 US Endocrinology, 2006;(2): DOI: http://doi.org/10.17925/USE.2006.00.02.1q
Authors: Annemarie Armani, Keith C Ferdinand
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Type-2 diabetes, which involves a perilous clustering of cardiovascular risk factors, primarily elevated blood pressure, atherogenic dyslipidemia and increased vascular thrombosis, affects 18 million Americans and is expected to reach almost epidemic proportions in the next decade.1 Persons with type-2 diabetes are at a dramatically increased risk for the development of cardiovascular events, specifically acute myocardial infarction (MI) and stroke. A diagnosis of diabetes presents the same cardiovascular risk as those who have already had MI, deeming it a ‘coronary risk equivalent’.2 More than 65% of deaths in diabetes patients are attributed to heart and vascular disease.1 Although mortality from coronary heart disease (CHD) has been decreasing overall in the US in the last several decades, the increasing prevalence of type-2 diabetes may ultimately slow or reverse this trend.

Article:

Racial and ethnic minorities in the US are disproportionately afflicted with diabetes (see Figure 1 and Table 1) and type-2 diabetes is considerably more common in African-Americans than in whites.3–5 In the Atherosclerosis Risk in Communities Study, the incidence of diabetes was 2.4 times greater in African- American women and 1.5 times greater in African- American men than in their white counterparts.6


Racial and ethnic minorities in the US are disproportionately afflicted with diabetes (see Figure 1 and Table 1) and type-2 diabetes is considerably more common in African-Americans than in whites.3–5 In the Atherosclerosis Risk in Communities Study, the incidence of diabetes was 2.4 times greater in African- American women and 1.5 times greater in African- American men than in their white counterparts.6

Diabetes also disproportionately affects Hispanics in the US.7 Hispanic/Latino Americans are 1.5 times more likely, with Mexican Americans—the largest Hispanic/Latino subgroup—more than twice as likely to have diabetes as non-Hispanic whites of similar age. Residents of Puerto Rico are also 1.8 times more likely to have diagnosed diabetes than non-Hispanic white Americans. Although studies have determined that overweight and obesity contribute heavily to racial/ethnic disparities in diabetes prevalence, Hispanics still have higher prevalence of diabetes than non-Hispanic whites at each level of body mass index (BMI).8With the presence of obesity, insulin resistance and diabetes in Hispanic Americans, it is expected that rates of CHD will markedly increase over the next several years. Native Hawaiians—and Japanese and Filipino residents of Hawaii—are also at double the risk of having diagnosed diabetes compared with white Hawaiian residents. Even at low levels of BMI, many Asian populations appear to be susceptible to the development of excessive abdominal obesity, which causes them to develop insulin resistance at lower thresholds than those of Caucasians9 and, as a consequence, Asian populations are seeing increasing rates of diabetes.10 Native Americans have the highest rates of diabetes, at 16%, which is more than double (2.2 times) the prevalence in non-Hispanic whites of similar age. Mortality rates due to diabetes, however, are highest in African-Americans, which is most probably due to the presence of concomitant risk factors, most prominently comorbid hypertension.11–13 It is expected, with the persistent growth of minority populations, that the epidemic of diabetes and subsequent cardiovascular disease (CVD) will only continue to rise over the next few decades.

Management of Cardiovascular Risk Factors

Lifestyle Modification
Numerous studies have shown that attention to lifestyle modification can dramatically reduce progression to type-2 diabetes.14–16 However, this can be particularly challenging in racial and ethnic minority groups and the rise in the rate of obesity has been greatest in minorities. Achieving and sustaining weight loss is often very challenging, but remains extremely important in reducing the cardiovascular risk associated with type-2 diabetes17 and it has been suggested in at least one study of overweight patients with type-2 diabetes that intentional weight loss may lead to as much as a 25% reduction in total mortality over 12 years.18 Current guidelines also recommend regular, moderate physical activity and here, too, all cardiometabolic risk factors improve with sustained physical activity.19 In particular, the Diabetes Prevention Program11 showed that walking 30 minutes a day, six days a week—combined with dietary changes, with average weight loss of 5% or 7%—led to a reduction in diabetes of approximately 60%.20 Racial and ethnic minority groups are often culturally bound to diet and physical activity habits, and the clinician needs to be aware of these potential barriers when attempting to identify and manage these factors.

Hypertension
Both the American Diabetes Association and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure set the target goal of <130/80 millimetres of mercury (mmHg) in patients with diabetes. Most patients with type-2 diabetes and elevated blood pressure will require two or more agents to lower blood pressure to the recommended goal of <130/80mmHg21, which is particularly the case for African-Americans.22 Initial drug therapy should utilize agents that have been demonstrated to reduce CVD and renal risk in patients with diabetes, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, diuretics and calcium-channel blockers (CCBs).21 Considering the increased risk of CHD with type-2 diabetes, beta-blockers, and ACE inhibitors should be considered as initial therapy for hypertension, especially in patients >55 years of age or with documented atherosclerosis.23,24 There was concern that thiazide diuretics may cause glucose intolerance and new-onset diabetes. However, in the diabetic cohort of The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, chlorthalidone—a thiazide-type diuretic—was effective in preventing CVD. Recent evidence has suggested that blockers of the renin-angiotensin system may actually prevent new-onset diabetes, although the recent Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication has not confirmed this.25 Within African-Americans, the antihypertensive responsiveness to monotherapy with ACE inhibitors, ARBs, and beta-blockers may be less than the response to diuretics and CCBs, but these differences are corrected when diuretics are added to the neurohormonal antagonists. The International Society on Hypertension in Blacks has crafted guidelines and an algorithm to guide ideal management of high blood pressure in African Americans.22 Of note, however, African-American patients with systolic blood pressure >15mmHg or a diastolic blood pressure >10mmHg above goal should be treated with first-line combination therapy. Also currently emerging are data on South Asians and their high rates of CHD, which may be due to their high rates of hypertension, although this is reported mainly from non-American epidemiological studies.26 The World Health Organization has reported that Indian men in the age range of 40 to 55 years have the highest blood pressure among populations from 20 other developing countries, but more information is clearly needed.27

Dyslipidemia
Multiple clinical trials have demonstrated the benefit of statin therapy in patients with type-2 diabetes and elevated low-density lipoprotein cholesterol (LDL-C), particularly in secondary prevention of CVD.28–31 In the Heart Protection Study (HPS), diabetic participants showed a highly significant reduction of 22% (p <0.0001) in major coronary events, strokes, and revascularisation with simvastatin.28,32 With regard to primary prevention, the HPS also demonstrated that the proportion of first major vascular events was reduced by 33% in diabetic patients (p = 0.0003).32 Furthermore, in diabetic, hypertensive patients with normal or average LDL-C levels, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) demonstrated benefit in type-2 diabetics with atorvastatin 10 milligrams (mg) versus placebo in the reduction of the risk for nonfatal MI and fatal CHD by 36% (p = 0.0005).33 Recently, the Collaborative Atorvastatin Diabetes Study (CARDS) of 2,838 adults with type-2 diabetes and, again, no history of CVD or hyperlipidemia demonstrated a 36% reduction in acute CHD events, 48% reduction in stroke, and 27% reduction in death rate (p = 0.059) in patients on atorvastatin 10mg.34 This study confirmed that statin therapy reduces first CVD events in patients with type-2 diabetes without high cholesterol in primary prevention.

There do not appear to be significant differences in LDL-C and total cholesterol levels across racial and ethnic-minority groups. Lipid goals, however, are based on individualised risk stratification, which is where minority patients are often at higher risk. African-Americans have a propensity to risk-factor clustering. Current National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (NCEP ATP III) guidelines recommend, for a patient with type-2 diabetes who does not have documented CVD, a goal LDL-C of less than 100mg per decilitre (mg/dL).35 The NCEP ATP III issued an interim report in 2004,35 based on the implications of five recent clinical trials, including ASCOT and the HPS,36 making available the optional LDL-C goal of <70mg/dL for patients with established CVD and those at ‘very high risk’ of future CVD events, including those with type-2 diabetes mellitus.35 Furthermore, the results of CARDS, which were subsequently published, provide further rationale for initiation of statin therapy in patients with type-2 diabetes and CVD, regardless of baseline LDL-C level.34 Admittedly, these trials contained an underrepresentation of racial and ethnic minorities. Antiplatelet Therapy
Type-2 diabetes, especially when combined with hypertension and atherogenic dyslipidemia, is associated with a prothrombotic state. Meta-analyses of multiple studies, including large-scale diabetes trials, support the use of low-dose aspirin therapy (75mg–162mg per day), which is routinely recommended for primary prevention of CVD in patients with diabetes older than 40 years of age or with multiple risk factors and is also indicated for secondary prevention in all patients with overt CVD, if no contraindications exist.37 Other antiplatelet agents (e.g. clopidogrel) may be considered as a substitute in the case of aspirin allergy.Aspirin therapy is extremely inexpensive with no cost barrier, which can often disenfranchise economically disadvantaged racial/ethnic minorities, and should be utilised in all patients with type-2 diabetes. However, despite its proven efficacy, aspirin therapy is still currently underutilized in patients with diabetes.38

Intensive Multifaceted Strategy
Ultimately, it is the combination and intensity of therapeutic lifestyle changes and pharmacological risk management that are key to prevention of cardiovascular events in the diabetic population. In a study of combined intense lifestyle and pharmacological lipid treatment, 409 patients with coronary-artery disease were given comprehensive diet plans, monthly followup and extensive cardiovascular medication in addition to lipid-lowering therapy. This led to a 78% risk reduction for cardiovascular events versus those with usual care (no dietary interventions, little or no lipidlowering therapy, continued smoking; p<0.003).39 Similarly, in the European Steno-2 Study of patients with type-2 diabetes and macroalbuminuria, 80 patients were randomly assigned to receive conventional guideline-appropriate treatment and the remaining 80 received multifactorial intensive therapy targeting multiple CHD risk factors.40 The mean follow-up was 7.8 years and the mean patient age was 55.1 years. As expected, the multifactorial treatment group demonstrated a decrease of approximately 50% in cardiovascular and macrovascular events (p=0.008). These studies, although not in racial and ethnic minorities, provide further documentation that the management of global risk is important by the utilization of intensive treatment with multifactorial approaches to cardiovascular risk reduction.

Summary
It is widely known that the incidence of type-2 diabetes is increasing worldwide, especially in industrialised, Westernized populations, and currently affects approximately one in four adults. It is disproportionately affecting patients of ethnic and racial minority populations, putting them at increased risk for the development of CVD, including MI and stroke. Aggressive management and control to optimal levels of blood pressure, lipids and appropriate use of low-dose aspirin therapy could, theoretically, prevent much of the large burden of cardiovascular events in these patient populations. Although typically under-represented in clinical trials, the current recommendations for management of these at-risk populations must include intensive therapeutic lifestyle changes, appropriate antihypertensive medications and lipid-modifying therapy. Risk reduction with statin therapy in patients either with or without dyslipidemia suggests a great opportunity to further reduce risk. Different racial and ethnic groups may be at unique risk, whether due to diet or eating habits, physical activity or smoking. Only with a combined intensive and culturally sensitive multifactorial approach can the cardiovascular morbidity and mortality then begin to decline in these at-risk patients.

Article Information:

References

  1. National diabetes fact sheet: General information and national estimates on diabetes in the United States; US Department of Health and Human Services, Centers for Disease Control and Prevention (2004).
  2. “Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults”,The Expert Panel, Archives of Internal Medicine (1988); 148 (1): pp. 36–69.
  3. King H,Aubert RE, Herman WH, Diabetes Care (1998); 21 (9): pp. 1414–1431.
  4. Zimmet P, Alberti KG, Shaw J, Nature (2001); 414 (6865): pp. 782–787.
  5. Gavin JR, III, Transactions of the American Clinical and Climatological Association (1995); 107: pp. 213–223; discussion 23–25.
  6. Brancati FL, Kao WH, Folsom AR, et al., The Journal of the American Medical Association (2000); 283 (17): pp. 2253–2259.
  7. Morbidity and Mortality Weekly Report (1999); 48 (1): pp. 8–12.
  8. Mokdad AH,Ford ES, Bowman BA, et al., The Journal of the American Medical Association (2003); 289 (1): pp. 76–79.
  9. Gill TP, Asia Pacific Journal of Clinical Nutrition (2001); 10 (2): pp. 85–89.
  10. Oldroyd J, Banerjee M, Heald A, Cruickshank K, Postgraduate Medical Journal (2005); 81 (958): pp. 486–490.
  11. Goldschmid MG, Domin WS, Ziemer DC, et al., Diabetes Care (1995); 18 (7): pp. 955–961.
  12. Arfken CL, Salicrup AE, Meuer SM, et al., Archives of Internal Medicine (1994); 154 (22): pp. 2597–2602.
  13. Falkner B, Kidney International Supplement (2003); Feb (83): pp. S27–30.
  14. Tuomilehto J, Lindstrom J, Eriksson JG, et al., The New England Journal of Medicine (2001); 344 (18): pp. 1343–1350.
  15. Knowler WC, Barrett-Connor E, Fowler SE, et al. The New England Journal of Medicine (2002); 346 (6): pp. 393–403.
  16. Wadden TA, Berkowitz RI,Womble LG, et al. The New England Journal of Medicine (2005); 353 (20): pp. 2111–2120.
  17. National Institutes of Health, Obesity Research (1998); 6 (Suppl. 2): pp. 51S–209S.
  18. Williamson DF, Madans J, Anda RF, et al., International Journal of Obesity and Related Metabolic Disorders (1993); 17 (5): pp. 279–286.
  19. Lakka TA, Laaksonen DE, Lakka HM, et al., Medicine and Science in Sports and Exercise (2003); 35 (8): pp. 1279–1286.
  20. Diabetes Care (2002); 25 (12): pp. 2165–2171.
  21. Chobanian AV, Bakris GL, Black HR, et al., The Journal of the American Medical Association (2003); 289 (19): pp. 2560–2572.
  22. Douglas JG, Bakris GL, Epstein M, et al., Archives of Internal Medicine (2003); 163 (5): pp. 525–541.
  23. Braunwald E, Antman EM, Beasley JW, et al., Journal of the American College of Cardiology (2002); 40 (7): pp. 1366–1374.
  24. Yusuf S, Sleight P, Pogue J, The New England Journal of Medicine (2000); 342 (3): pp. 145–153.
  25. Bosch J,Yusuf S, Gerstein HC, et al., The New England Journal of Medicine (2006); 355 (15): pp. 1551–1562.
  26. Burden AC, International Journal of Clinical Practice (1998); 52 (6): pp. 388–394.
  27. The World Health Organization (WHO), Surveillance of Major Noncommunicable Diseases in the South East Region Report of an Intercountry Consultation,WHO/Regional Office for South-East Asia (ed.) (2000).
  28. Heart Protection Study Collaborative Group, Lancet (2002); 360: pp. 7–22.
  29. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, The New England Journal of Medicine (1998); 339 (19): pp. 1349–1357.
  30. Sacks RM, Pfeffer MA, Moye LA, et al., The New England Journal of Medicine (1996); 335: pp. 1001–1009.
  31. Scandinavian Simvastatin Survival Study Group, Lancet (1994); 344: pp. 1383–1389.
  32. Collins R,Armitage J, Parish S, et al., Lancet (2003); 361 (9374): pp. 2005–2016.
  33. Sever PS, Poulter NR, Dahlof B, et al., Diabetes Care (2005); 28 (5): pp. 151–157.
  34. Colhoun HM, Betteridge DJ, Durrington PN, et al., Lancet (2004); 364 (9435): pp. 685–696.
  35. Grundy SM, Cleeman JI, Merz CNB, et al., Circulation (2004); 110 (2): pp. 227–239.
  36. The Journal of the American Medical Association (2001); 285 (19): pp. 2486–2497.
  37. American Diabetes Association, Diabetes Care (2005); 29 (Suppl. 1): pp. S4–36.
  38. Colwell JA, Diabetes Care (2004); 27 (Suppl. 1): pp. S72–73.
  39. Sdringola S, Nakagawa K, Nakagawa Y, et al., Journal of the American College of Cardiology (2003); 41 (2): pp. 263–272.
  40. Gaede P,Vedel P, Larsen N, et al., The New England Journal of Medicine (2003); 348 (5): pp. 383–393.
  41. Harris MI, Diabetes Care (1991); 14 (Suppl. 3): pp. 639–648.
  42. 1999–2001 National Health Interview Survey and 1999–2000 National Health and Nutrition Examination Survey estimates projected to year 2002; 2002 outpatient database of the Indian Health Service.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72